BioMADE Flagship Biomanufacturing Facility Progresses in Maple Grove

In April 22, 2026, the BioMADE Flagship Biomanufacturing Facility reached a pivotal milestone with the selection of a primary engineering and construction partner to lead its physical transformation. This decision moved the project from the conceptual phase into active development, focusing on outfitting the 122,000-square-foot site with specialized industrial equipment. By securing the expertise needed for high-tech installation, including massive 25,000-liter fermenters, the facility is positioned to bridge the gap between laboratory research and commercial-scale production for bio-based chemicals and materials.

Earlier in January 2026, the facility was recognized as a cornerstone of the regional science and technology corridor’s long-term growth strategy. Its integration into this burgeoning hub signaled a shift toward sustainable manufacturing, leveraging local agricultural resources to create high-value products for both national security and consumer markets. This period solidified the project’s role as a catalyst for economic development, promising to bring technical jobs and innovative infrastructure to the area as it moves toward its scheduled operational launch in 2027.

Backed by a combined $132 million in funding from the U.S. Department of Defense and the Minnesota Department of Employment and Economic Development (DEED), the project will serve as a national model for scaling biotechnology innovations. Minnesota is contributing $50 million, with the remainder provided by the Department of Defense, which originally helped launch BioMADE in 2020 with an $87.5 million investment to support defense-focused bioindustrial development.

The Maple Grove facility will house two 25,000-liter industrial fermenters and a full suite of downstream processing equipment—including centrifuges, membrane filtration systems, ion exchange columns, crystallizers, and drying capabilities—allowing for both liquid and solid end products. Lab resources will support analytical testing and process development, enabling a range of companies to transition their innovations from lab-scale prototypes to commercial readiness.

Bridging the gap

“While the U.S. has long led in biotech research, there’s a critical gap in infrastructure to scale those breakthroughs into production,” said BioMADE CEO Douglas Friedman. “This new facility will help bridge that gap by providing the tools and space needed to advance innovation, not just for commercial applications but for national defense as well.”

BioMADE collaborates with companies of all sizes—including local names like Wayzata-based Cargill and national players such as Lockheed Martin—to develop sustainable consumer products like plant-based plastics, textiles, and personal care goods. The Maple Grove site will particularly focus on bio-based chemicals and materials and will feature enhanced safety protocols to handle volatile substances.

BioMADE’s new Maple Grove biomanufacturing facility, it will serve diverse industry needs, offering support across product development stages—from early testing to pilot-scale production and refinement. BioMADE also plans to integrate on-site education and workforce development programs, offering hands-on lab training and upskilling opportunities for students and existing workers. The nonprofit notes that every job created in the bioindustrial sector can generate up to 11 additional jobs across the U.S. economy.

New facility opening, jobs

The facility is expected to open in 2027 and will initially create around 25 full-time jobs, with potential for expansion as operations grow.

Additionally, BioMADE’s announcement joins a broader surge in U.S. biomanufacturing investment. Companies like Amgen have committed major resources, such as a $900 million Ohio expansion bringing 350 new jobs, while industry leaders including Merck, Novartis, Eli Lilly, Roche, Johnson & Johnson, and AbbVie have pledged more than $166 billion in U.S. manufacturing investments over the next decade. And recently, Genentech have also broken ground on their first facility in the East Coast in Holly Springs, North Carolina. The $700 million investment is a strategic expansion designed to pioneer the next generation of medicines.

The expansion by BioMADE reflects a broader surge in U.S. biomanufacturing investment, a trend also underscored by Novartis as it completes its manufacturing network with a new API facility in North Carolina.

BioMADE Maple Grove Biomanufacturing Facility

Project Overview

Organization: BioMADE (nonprofit headquartered at University of Minnesota’s St. Paul campus)

Project: New flagship biomanufacturing facility

Location: 7500 Meridian Circle North, Maple Grove, MN (near Highway 169 and Elm Creek Boulevard)

Building Size: 122,000 square feet i.e. repurposed existing building

Expected Opening: 2027

Initial Job Creation: Approximately 25 full-time positions

Funding

Total Investment: $132 million

Funding Sources:

U.S. Department of Defense: $82 million

Minnesota Department of Employment and Economic Development (DEED): $50 million

Production Capabilities at BioMADE’s Upcoming Maple Grove Biomanufacturing Site

Two 25,000-liter industrial fermenters

Complete downstream processing suite that is centrifuges, membrane filtration, ion exchange columns, crystallizers, and drying systems

Capacity for both liquid and solid end products

Additional Resources:

Laboratory facilities for analytical testing

Process development capabilities

Enhanced safety protocols for volatile substan

Construction Review